Skip to main content

Table 5 Main sociodemographic and clinical characteristics of patients from other National Registries

From: Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry

 

SEPAR IPF National Registry

INSIGHTS-IPF [17]

Finnish IPF [18]

Swedish IPF [19]

Indian IPF Ω [20]

Australian IPF [21]

EMPIRE IPF [22]

EurIPFreg [23]

Country

Spain

Germany

Finland

Sweden

India

Australia

Czech part

Europe b

Number of patients, n

608

502

111

71

148

647

514

525

Males, %

80.8

77.9

60.4

70.4

73.6

67.7

69.8

73.7

Age mean years

70.2

68.7

73.5

70.0

64.7

70.9

67.0

68.1

BMI mean Kg/m2

28.2

27.6

28.1

27.0

28.7

28.7

27.2

Ex-smoker, %

63.7

60.2

45.9

56.4

71.7

65.4

6MWD, mean m

423.5

267.6

 

420

 

388

FVC, mean % of predicted

77.6

72.2

80.4

72.3

57.5

81.0

80.0

68.4

DLCO, mean % of predicted

48.5

35.5

57.3

52.1

48.4

45.6

42.1

Symptoms indicative of IPF at diagnosis, %

 Dyspnoea

84.7

85.9

44.7 a

90.1

 Inspiratory bibasilar crackles

89.6

79.0

95.5

 Cough

62.8

74.9

46.6 a

53.2

Procedures for definitive diagnosis, %

 HRCT

99.2

90.2

72

 Surgical lung biopsy

26.5

34.1

14

32 → 8 c

 Multidisciplinary discussion

23.8

21.8

20

  1. a From patients with available data; b EurIPFreg, the European IPF Registry has collected information of hospitals from Germany, France, United Kingdom, Italy, Spain, Hungary, and Czech Republic; c 32% in 2009 and 8% in 2016; Ω IPF patients are part of the interstitial lung disease registry completed in India
  2. SD standard deviation, BMI body mass index, 6MWD 6-min walk distance, FVC forced vital capacity, DLCO diffusing capacity of the lung for carbon monoxide, HRCT high-resolution computed tomography